Reference
Satankova M, et al. Effect of erlotinib in 2nd and 3rd line anticancer treatment in patients with squamous cell lung cancer-Case series. Klinicka Onkologie 30: 131-135, No. 2, Jan 2017. Available from: URL: http://doi.org/10.14735/amko2017131 [Czech; summarised from a translation] - CzechRepublic
Rights and permissions
About this article
Cite this article
Erlotinib. Reactions Weekly 1658, 186 (2017). https://doi.org/10.1007/s40278-017-32383-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-017-32383-5